Aktuellt
SENASTE
Redeye endorses the news that Curasight has appointed a CRO, ABX-CRO, to conduct the upcoming phase II trial with uTRACE in prostate cancer, which is part of the collaboration with Curium. According to Curasight, the study will be conducted in two parts (one in Denmark and Sweden and the second expanded to Germany and the US) and will include prostate cancer patients under “active surveillance”. Overall, this indicates that the company is proceeding according to plan, and we hope to return with a more thorough comment soon once we know more about the trial and the timeline.
LÄS MER
